

Retinal microvascular alterations related to diabetes assessed by optical coherence tomography angiography

A cross-sectional analysis

Julien Gozlan, MD^a, Pierre Ingrand, MD, PhD^{b,c}, Olivier Lichtwitz, MD^a, Agathe Cazet-Supervielle, MD^a, Léa Benoudis, MD^a, Michele Boissonnot, MD^a, Samy Hadjadj, MD, PhD^{c,d,e}, Nicolas Leveziel, MD, PhD^{a,c,f,*}

Abstract

Fluorescein angiography has been so far the gold-standard test to assess diabetic macular ischemia (DMI), a cause of irreversible visual impairment in diabetic patients. The aim of this study was to investigate foveal avascular zone (FAZ) and perifoveal microcirculation changes in eyes with nonproliferative diabetic retinopathy (NPDR) using optical coherence tomography angiography (OCTA), a new and noninvasive vascular imaging technique.

Cross-sectional study including eyes of diabetic patients with NPDR.

All patients underwent medical history, best-corrected visual acuity (BCVA) measurement, slit-lamp and fundus examination, multicolor imaging, SD-OCT, and swept-source OCT. OCTA was performed in order to assess macular superficial and deep capillary plexus, and swept-source OCT was performed to evaluate the central choroidal thickness.

Fifty-eight eyes of 35 patients with a mean age of 61.8 years (\pm 12.1) with mean HbA1C level of 7.6% (\pm 1.5) were included in this study. Among them, 19 eyes had mild NPDR, 24 eyes had moderate NPDR, and 15 eyes had severe NPDR. There was a significant progression between NPDR stages for FAZ grade (P < 0.0001), surface (P = 0.0036) and perimeter (P = 0.0001), and for superficial capillary plexus nonperfusion index (NPI) (P = 0.0009). Moreover, a significant correlation was found between NPI and BCVA (P = 0.007).

OCT angiography is a useful noninvasive tool to explore early phases of diabetic retinopathy, which are not routinely explore with fluorescein angiography and not precisely enough with color photographs. NPI and foveal avascular zone parameters are correlated with glycated hemoglobin in patients with NPDR. If confirmed by further studies, these results could represent a mean to sensibilize diabetic patients to their disease.

Abbreviations: BCVA = best-corrected visual acuity, DMI = diabetic macular ischemia, ETDRS = Early Treatment Diabetic Retinopathy Study, FAZ = foveal avascular zone, HbA1C = glycated hemoglobin A1C, NPDR = nonproliferative diabetic retinopathy, NPI = nonperfusion index, OCTA = optical coherence tomography angiography.

Keywords: capillary occlusion, capillary plexus, diabetic retinopathy, ischemia, macula, OCT angiography, retinal Imaging

Editor: Dinesh Garg.

Authorship: JG, ACS, MB and NL: involved in conception and design; JG, Pl and NL: analysis and interpretation; JG, OL, ACS, LB, and MB: data collection; JG, Pl, SH, NL: writing the article; JG, Pl, NL: revision; Pl and NL: final approval.

This study was approved by ethics committee of the French Society of Ophthalmology (IRB 00008855) and followed the tenets of the Declaration of Helsinki. All patients gave their informed consent for inclusion in this study. This study was planned as a clinical observational study, and is consequently not registered at any clinical registry sites.

The authors have no funding and conflicts of interest to disclose.

^a Department of Ophthalmology, CHU Poitiers, ^b Public Health Department, University of Poitiers, ^c University of Poitiers, UFR de Médecine et Pharmacie, ^d Biostatistics, INSERM CIC 1402, Centre d'investigation clinique, University Hospital of Poitiers, ^e Diabetology Department, Poitiers – Coordinating Center of the DIAB2NEPHROGENE Study, ^f INSERM 1084, University of Poitiers, France.

* Correspondence: Nicolas Leveziel, Department of Ophthalmology, Poitiers University Hospital, 2 rue de la Milétrie, 86021 Poitiers Cedex, France (e-mail: nicolas.leveziel@yahoo.fr).

Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Medicine (2017) 96:15(e6427)

Received: 3 May 2016 / Received in final form: 18 December 2016 / Accepted: 27 February 2017

http://dx.doi.org/10.1097/MD.00000000006427

1. Introduction

Diabetes mellitus is a widespread condition affecting 366 million people worldwide.^[1] Diabetic retinal disease is one of the leading causes of blindness in Western countries.^[2] Visual impairment in diabetes is usually related to 3 different mechanisms: diabetic macular edema, complications of retinal neovascularization (mainly vitreous hemorrhage and retinal detachment), and diabetic macular ischemia (DMI).

DMI has been reported to affect approximately 7% of patients with diabetic retinopathy.^[3] This pathological condition is characterized by enlargement of the physiological capillary-free zone located at the center of the macula, also known as the foveal avascular zone (FAZ), along with perifoveal capillary dropout.

Various methods have been used to assess FAZ and perifoveal microcirculation: in vitro techniques on enucleated eyes as well as in vivo techniques, with psychophysical methods, fundus photography, and fluorescein angiography.^[4–7]

The latter remains the gold-standard test, as it mainly explores the superficial capillary plexus which contains the perifoveal anastomotic capillary arcade defining the limits of the FAZ.^[8–10]

Optical coherence tomography angiography (OCTA) is a newly available retinal vascular imaging technique, which is able to separately visualize superficial and deep macular capillary plexus.^[11]

The aim of this study was to investigate foveal avascular zone and perifoveal microcirculation changes relative to mild, moderate, and severe nonproliferative diabetic retinopathy (NPDR) using the OCTA.

2. Methods

2.1. Experimental design

This cross-sectional study included diabetic patients affected with NPDR with appointments in the Department of Ophthalmology during July 2015. Patients were screened after informed consent was obtained. This study was performed according to the Declaration of Helsinki and was approved by the ethics committee of the French Society of Ophthalmology (institutional review board 00008855 Société Française d'Ophtalmologie).

2.2. Inclusion and exclusion criteria

Inclusion criteria were age of 18 years or more and presence of an NPDR in the studied eye, as assessed on nonmydriatic fundus color photographs covering the Early Treatment Diabetic Retinopathy Study (ETDRS) 7-standard fields. For each patient, one or both eyes meeting those criteria were included.

Noninclusion criteria were: presence of media opacities preventing reliable retinal imaging and fundus examination, macular edema with retinal thickness preventing good visualization of the FAZ by OCTA, other retinal diseases (age-related macular degeneration, macular hole, epiretinal macular membrane, foveoschisis, and foveal hypoplasia), history of vitreoretinal surgery, and history of macular laser grid.

2.3. Data collection

All patients included in the study underwent comprehensive ophthalmologic examination including best-corrected visual acuity (BCVA) measurement on ETDRS scale, slit-lamp biomicroscopic and fundus examination, Spectral-Domain Optical Coherence Tomography (volume mode of 49 B-scans, centered on the fovea), macular 30 degree MultiColor retinography (Spectralis HRA+OCT; Heidelberg Engineering, Heidelberg, Germany) as well as ETDRS 35 degree 7-standard fields color retinal photographs (Topcon TRC; Topcon, Tokyo, Japan) for retinal assessment, Swept-Source Optical Coherence Tomography (DRI OCT-1 Atlantis; Topcon, Tokyo, Japan) for choroidal thickness assessment, and Optical Coherence Tomography Angiography (Optovue RTVue XR Avanti; Optovue Inc, Fremont, California) for macular retinal vascularization assessment.

Diabetic retinopathy was graded according to the International Diabetic Retinopathy Severity Scale, as previously described.^[12]

Demographic data (age, gender), general medical history (smoking, high blood pressure, hyperlipidemia, cerebral vascular accident, myocardial infarction, and amputation), diabetic medical history (type of diabetes, disease duration, most recent level of glycated hemoglobin, oral diabetes medication, and insulin therapy), and ophthalmologic history (cataract surgery, intravitreal antivascular endothelium growth factor injections) were also collected.

2.4. Optical coherence tomography angiography

For each included eye, an OCTA of the superficial and deep capillary plexus was performed as previously described.^[11] This

instrument uses a novel noninvasive and dyeless technique, which performs repeated sequential Optical Coherence Tomography cross-sectional scans at the same location on the retina in order to capture the dynamic motion of the erythrocytes. Thus, this device permits high-resolution imaging of the perfused vascular structure within specific layers of the retina with a 22- μ m beam width. It has an A-scan rate of 70,000 scans per second, using a light source centered on 840 nm and a band-width of 45 nm. The tissue resolution is 5 μ m axially, and the beam is 22- μ m wide.

A $3 \times 3 \,\text{mm}$ OCTA acquisition centered on the fovea was performed. The "en face" image was then automatically segmented with an inner boundary $3\,\mu\text{m}$ beneath the internal limiting membrane and an outer boundary $15\,\mu\text{m}$ beneath the inner plexiform layer (IPL) to obtain images of the superficial capillary plexus. The segmentation was carried out with an inner boundary $15\,\mu\text{m}$ beneath the IPL and an outer boundary $70\,\mu\text{m}$ beneath the IPL in order to obtain deep capillary plexus images.^[13]

2.5. Superficial and deep capillary plexus image analysis

Each superficial capillary plexus image was analyzed using ImageJ 1.48 software (NIH, Bethesda, MD).^[13] We manually traced FAZ contours in order to assess its different parameters. After setting the image scale to $3 \times 3 \text{ mm}$ in the software parameters, we were able to automatically obtain measurement of the perimeter and area of the FAZ.

Similarly, the surface of the central nonperfused area visible on the deep capillary plexus image was measured.

Furthermore, a nonperfusion index (NPI) of the total superficial capillary plexus image area was assessed using the same software by calculating the ratio between the cumulative area of pixels of which the brightness was beneath the value of 45 and the total area of the picture (Fig. 1).

2.6. FAZ contour assessment

The extent of FAZ damage was also assessed using the ETDRS gradation system from 0 (normal FAZ) to 4 (FAZ contours completely altered), as previously described.^[14,15]

2.7. Statistical analysis

Statistical analysis was performed with SAS software, version 9.3 (SAS Institute Inc, Cary NC). Qualitative variables are presented as number and percentage. Quantitative variables are presented as means and standard deviations. Nonparametric ANOVA comparing the 3 NPDR groups used the nonparametric Kruskal-Wallis test. Qualitative variables were compared by Fisher exact test. Univariate analysis of FAZ parameters was based on Spearman rank correlation coefficient when relating to quantitative variables and Mann-Whitney nonparametric test when relating to qualitative factors. Multivariate analysis used linear covariance analyses for each FAZ parameters. Covariates were entered in the analysis on a P-value less than 0.20 from the univariate analysis, then a backward elimination procedure retained only independently significant variables. A logarithmic transformation was performed in order to normalize variable distribution if necessary. P < 0.05 was considered statistically significant. In this exploratory analysis, no correction was applied to account for intraclass correlation between eyes belonging to the same patient.



Figure 1. Optical coherence tomography angiography superficial capillary scan of a right eye with moderate nonproliferative diabetic maculopathy. (Left) The foveal avascular zone appears to be enlarged, with presence of perifoveal capillary dropout (arrow). (Center) Semiautomatic selection of the foveal avascular zone (arrow). (Right) Automatic selection of nonperfused areas.

3. Results

3.1. Demographic data and medical history

Fifty-eight eyes of 35 patients (mean age = 61.8 ± 12.1 years) with NPDR were included in this study (Fig. 2).

Among those 35 patients, there were 22 men (63%) and 13 women (37%); type 2 diabetes affected 30 patients while 5 patients had type 1 diabetes. Mean diabetic duration was 18.3 ± 9.9 years, mean glycated hemoglobin A1C (HbA1C) level was $7.6 \pm 1.5\%$, and 22 patients (63%) had oral medication and 29 patients (83%) had insulin therapy. Cardiovascular history of smoking, high blood pressure, and dyslipidemia were present in the majority of patients. These results are presented in Table 1.

3.2. Ocular history, functional, and anatomical characteristics

Mean BCVA was 81.2 ± 12.3 letters (15–99). Only 1 eye had intravitreal antivascular endothelial growth factor history. Among the 58 included eyes, 19 eyes (32.8%) had mild NPDR, 24 eyes (41.4%) had moderate NPDR, and 15 eyes (25.8%) had severe NPDR (Table 2).

73 eyes of 37 patients screened	
	Excluded from the study : - diabetic macular edema > 350 µm : 2 eyes - macular laser : 1 eye - foveal hypoplasia : 6 eyes - epiretinal membrane : 2 eyes - ocular ischemia : 1 eye - age-related macular degeneration : 1 eye - media opacity : 2 eyes
58 eyes of 35 patients included	
Figure 2. Flow	w chart of study patients.

3.3. NPDR group comparison analysis

Table 3 summarizes the comparison analysis between the 3 NPDR groups. No significant differences for age, sex, medical history, diabetes history, and ocular characteristics were observed among the groups, except for spherical equivalent (P=0.034), oral diabetic medication (P=0.002), and HbA1C (P=0.049).

3.4. Relationship between NPDR status and OCTA data

There was a statistical difference between the 3 NPDR groups for FAZ grade (P < 0.0001), FAZ surface (P = 0.0036), FAZ perimeter (P = 0.0001), superficial capillary plexus (SCP) NPI (P = 0.0009), and deep capillary plexus (DCP) central non-

Table 1

Patient demographic characteristics and medical history.

• •	-
	All patients (n=35)
Age, y	
Mean (SD)	61.8 (12.1)
Range	38–83
Sex, n (M/F)	22/13
Medical history	
Smoking, n, %	18 (51%)
High blood pressure, n, %	26 (74%)
Hyperlipidemia, n, %	20 (57%)
Amputation, n, %	3 (9%)
Cerebrovascular accident, n, %	1 (3%)
Myocardial infarction, n, %	8 (23%)
Diabetes history	
Type of diabetes, n (1/2)	5/30
Diabetes duration, y	
Mean (SD)	18.3 (9.9)
Range	4–40
HbA1C, %	
Mean (SD)	7.6 (1.5)
Range	5.3–11.2
Treatment	
Oral medication, n, %	22 (63%)
Insulin therapy, n, %	29 (83%)

HbA1C = glycated hemoglobin A1C, SD = standard deviation.

Table 2					
Ocular histo	orv. functional	, and ana	tomical cha	aracteristic	s.

	All eyes (n=58)
Spherical equivalent (D)	
Mean (SD)	0.22 (1.22)
Range	-2.63 to +2.63
BCVA (letters)	
Mean (SD)	81.2 (12.3)
Range	15-99
Lens status	
Phakic, n, %	41 (71%)
Pseudophakic, n, %	17 (29%)
Intravitreal anti-VEGF history, n, %	1 (2%)
Central retinal thickness, µm	
Mean (SD)	281 (28)
Range	226-349
Central choroidal thickness, µm	
Mean (SD)	237 (73)
Range	107-405
NPDR stage	
Mild NPDR, n, %	19 (33%)
Moderate NPDR, n, %	24 (41%)
Severe NPDR, n, %	15 (26%)

BCVA = best-corrected visual acuity, NPDR = nonproliferative diabetic retinopathy, SD = standard deviation, VEGF = vascular endothelial growth factor.

perfusion area surface (P = 0.0002). These results are reported in Fig. 3. Moreover, OCTA scans of the 3 different groups of NPDR are presented in Fig. 4.

3.5. Analyses of FAZ parameters

Univariate analysis found significant associations between pseudophakia and FAZ surface (P=0.033), between HbA1C

Table 3

and FAZ grade (P < 0.0001), surface (P = 0.0006), and perimeter (P=0.0136). NPI was related to amputation history (P=0.020), diabetes duration (P=0.014), HbA1C (P=0.039), and BCVA (P=0.019). These results are indicated in Table 4.

Multivariate analysis retained a positive correlation was observed between HbA1C and FAZ grade, surface, and perimeter. A negative correlation was found between BCVA and NPI. Smoking was also associated with FAZ grade and NPI. These results are reported in Table 4.

4. Discussion

Over the past decades, FA has been the gold standard procedure to explore DMI. However, it has limitations, the most common being fluorescein injection, which can trigger frequent benign symptoms such as nausea and, rarely, severe reactions such as anaphylactic shock.^[16] Moreover, there are specific drawbacks in this indication, as FA quality may not always be good enough for reliable analysis of FAZ, and retinal vascularization may be difficult to analyze in case of retinal pigment epithelium atrophy.^[17] Furthermore, given its potential complications, FA is not recommended during the initial stages of diabetic retinopathy. In this study, we performed detailed quantitative analysis of FAZ and perifoveal microcirculation to assess DMI in patients with NPDR using OCTA, a novel noninvasive technique that facilitates imaging of perfused retinal and choroidal vascular structures within specific layers. Recent literature shows that OCTA has a wide range of potential applications in ophthalmology, including glaucoma and chorioretinal disorders such as exudative age-related macular degeneration, macular telangiectasia type 2, and diabetic retinopathy.[18-20]

DMI assessment has a major impact on visual function, leading to loss of retinal sensitivity, loss of contrast sensitivity, electroretinographic changes, and lower visual acuity.^[21-23]

Comparison analysis between the 3	NPDR groups.			
	Mild NPDR (n=19)	Moderate NPDR (n=24)	Severe NPDR (n=15)	Р
Patient characteristics				
Age, mean (SD)	56.9 (11.0)	64.0 (9.7)	61.6 (14.6)	0.199
Sex, n (M/F)	13/6	13/11	13/2	0.101
Medical history				
Smoking, n, %	12 (63)	12 (50)	8 (53)	0.710
High blood pressure, n, %	14 (74)	16 (67)	13 (87)	0.418
Hyperlipidemia, n, %	10 (53)	16 (67)	7 (47)	0.469
Amputation, n, %	0 (0)	3 (13)	2 (13)	_
Cerebrovascular accident, n, %	0 (0)	0 (0)	1 (7)	-
Myocardial infarction, n, %	6 (32)	5 (21)	3 (20)	0.733
Diabetes history				
Type of diabetes, n (1/2)	6/13	1/23	2/13	0.051
Diabetes duration, mean (SD)	18.4 (10.4)	17.4 (9.8)	19.1 (8.2)	0.802
HbA1C, mean (SD)	7.1 (1.3)	7.6 (1.0)	8.5 (2)	0.049
Treatment				
Oral medication, n, %	8 (42)	21 (88)	7 (47)	0.002*
Insulin therapy, n, %	16 (84)	20 (83)	12 (80)	1.000
Ocular characteristics				
Spherical equivalent, mean (SD)	0.25 (1.42)	0.57 (1.03)	-0.36 (1.07)	0.034
BCVA ETDRS score, mean (SD)	85.9 (7.1)	76.9 (16.7)	81.9 (5.8)	0.075
Lens status, n (phakic/pseudophakic)	17/2	14/10	10/5	0.076
Intravitreal anti-VEGF history, n, %	0 (0)	0 (0)	1 (6.7)	_
Central retinal thickness, mean (SD)	279 (26)	277 (25)	290 (36)	0.270
Central choroidal thickness, mean (SD)	250 (695)	217 (62)	251 (92)	0.244

BCVA=best corrected visual acuity, ETDRS=Early Treatment Diabetic Retinopathy Study, HbA1C=glycated hemoglobin A1C, NPDR=nonproliferative diabetic retinopathy, SD=standard deviation. P values significant at 5% level, Kruskal-Wallis test.



Figure 3. Comparison of OCTA parameters according to the NPDR status. (A) FAZ grade, (B) FAZ surface (mm²), (C) FAZ perimeter (mm), and (D) nonperfusion index. Results expressed as mean and standard deviation. Significance *P*-values from the Kruskal–Wallis test. FAZ = foveal avascular zone, NPDR = nonproliferative diabetic retinopathy, OCTA = optical coherence tomography angiography.

Histopathologically, DMI has been shown to induce inner retinal changes, with loss of ganglion cells, attenuation of the inner nuclear layer, and hyalinization of the retinal capillary network.^[24]

In this study, retinal macular microvascularization evaluated by OCTA differed significantly according to the stage of NPDR. This is, to our knowledge, the first study investigating FAZ and perifoveal microcirculation in NPDR patients, using a noninvasive device available for daily clinical practice.

A statistical difference for each FAZ parameter (grade, surface, and perimeter) was observed between the NPDR groups, with a progressive increase of parameters according to NPDR stage. These results are not surprizing, as a significant increase in FAZ size is a well-known FA feature of diabetic retinopathy.^[25–28] Thus, OCTA is able to provide quantitative analysis of FAZ, and the results are equivalent to those achieved with FA.

Deep capillary plexus central nonperfused area was also significantly different between the 3 NPDR groups. However, OCTA image segmentation of the deep capillary plexus on OCT B-scan seemed relatively random and unreliable, and its clinical significance needs to be clarified.

Finally, a statistical difference for NPI between the 3 NPDR groups was observed, with a progressive increase with NPDR stage. This is, to our knowledge, the first study to evaluate thoroughly and quantitatively macular microvascularization within a 3×3 mm square centered on the fovea in diabetic patients using an automated tool. Previous studies mostly used, besides FAZ measurements, a perifoveal intercapillary area index requiring manual marking of intercapillary spaces surrounding the fovea, with a different measuring protocol from one study to another. In addition to being automated, NPI has the advantage of taking into account, in a single standardized measurement, both FAZ surface enlargement and perifoveal capillary dropout.

Moreover, unlike FAZ parameters, in this study NPI was significantly associated with BCVA. In the literature, the correlation between BCVA and FAZ surface has not been consistently established. Although it was observed in a small series of 15 patients conducted by Arend et al,^[29] it did not appear in a more recent retrospective study conducted by Sim et al^[30] on FA images of a large cohort of patients, who nevertheless found a strong significant and independent association between papillomacular ischemia and BCVA. Thus, in our study, correlation between BCVA and NPI represents a new argument underlining the importance of perifoveal circulation in the occurrence of visual impairment secondary to DMI.



Figure 4. Optical coherence tomography angiography (OCTA) scans of the three different groups of nonproliferative diabetic retinopathy. (A) mild NPDR; (B) moderate NPDR; (C) severe NPDR.

Table 4

					FAZ grade			FAZ surface			FAZ perimete	-	No	nperfusion in	dex
Qp A156 0.4156 0.243 4.0050 0.7765 0.765 0.766			z	m±SD or <i>r</i> s	Univariate <i>P</i>	Multivariate <i>P</i>	m±SD or <i>f</i> s	Univariate <i>P</i>	Multivariate <i>P</i>	m±SD or <i>t</i> s	Univariate <i>P</i>	Multivariate P	m±SD or <i>r</i> s	Univariate <i>P</i>	Multivariate P
Skit Famelia 19 216+107 0.689 0.37±0.16 0.19 0.57±0.16 0.236 Medical fistory No 28 210±1.32 0.30±0.12 0.30±0.12 0.30±0.17 0.30±0.10	Age		58	+0.156	0.243		+0:050	0.703		+0.050	0.730		+0.040	0.765	
Media 33 200 ± 132 $0.39\pm0.0\pm132$ 0.57 ± 0.06 0.57 ± 0.06 Media 8 20 ± 1.126 0.176 0.014 0.35 ± 0.16 0.36 ± 1.16 0.57 ± 0.06 0.075 0.01 Smoling Ns 22 21 ± 1.126 0.176 0.014 0.35 ± 0.16 0.39 ± 1.16 0.075 ± 0.06 0.075 ± 0.06 0.014 0.35 ± 0.16 0.014 0.35 ± 0.16 0.014 0.35 ± 0.16 0.014 0.35 ± 0.16 0.014 0.35 ± 0.16 0.014 0.33 ± 0.16 0.014 0.33 ± 0.16 0.014 0.33 ± 0.16 0.014 0.33 ± 0.16 0.014 0.32 ± 0.16 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.026 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.0111	Sex	Female	19	2.16 ± 1.07	0.689		0.37 ± 0.16	0.199		3.57 ± 1.45	0.412		0.54 ± 0.06	0.236	
		Male	39	2.00 ± 1.32			0.30 ± 0.12			3.21 ± 1.07			0.57 ± 0.06		
Smoking No 2 2 2 3 4 1 0<	Medical history														
	Smoking	No	26	2.31 ± 1.26	0.176	0.014	0.35 ± 0.17	0.430		3.68±1.49	0.232		0.54 ± 0.06	0.076	0.013
High blood pressure No 15 2.07 ± 153 0.933±016 0.35±016 0.35±006 0.010 0.55±006 0.013 0.55±006 0.013 0.014 0.014 0.014 0.014 0.016 0.010 0.016 0.010 0.014 0.014 0.016 0.010 0.014 0.014 0.014 0.016 0.010 0.014 0.016 0.010 0.010 0.010 0.011 0		Yes	32	1.84 ± 1.19			0.30 ± 0.09			3.05 ± 0.83			0.57 ± 0.06		
	High blood pressure	No	15	2.07 ± 1.53	0.993		0.35 ± 0.16	0.394		3.40 ± 1.37	0.797		0.56 ± 0.06	0.894	
HyperlipticheriaNo 5 2.23 ± 1.34 0.225 0.03 ± 0.13 0.05 ± 0.06 0.113 HyperlipticheriaNo 5 3.23 ± 1.54 0.255 ± 0.06 0.020 0.013 MutationNo 5 3.09 ± 1.25 0.38 ± 0.16 0.35 ± 0.06 0.020 0.013 MutationNo 5 3.09 ± 1.25 0.38 ± 0.16 0.35 ± 0.06 0.020 0.013 MutationNo 5 2.09 ± 0.08 0.38 ± 0.16 0.35 ± 0.16 0.25 ± 0.06 0.020 0.013 Mocardial infactionYes 5 2.09 ± 0.08 0.38 ± 0.12 0.36 ± 0.16 0.25 ± 0.06 0.020 0.013 Mocardial infactionYes 4 2.14 ± 1.17 0.432 0.38 ± 0.13 0.38 ± 0.13 0.25 ± 0.06 0.020 0.013 Mocardial infactionYes 4 2.14 ± 1.17 0.432 0.38 ± 0.13 0.38 ± 0.13 0.35 ± 0.06 0.020 0.013 Mocardial infactionYes 4 2.14 ± 1.17 0.432 0.38 ± 0.13 0.38 ± 0.12 0.36 ± 0.06 0.020 0.03 Motardial infactionYes 4 2.14 ± 1.10 0.424 0.23 ± 0.14 0.23 ± 0.06 0.026 0.38 ± 0.06 0.026 0.036 ± 0.06 0.026 Motardial infactionNo 1 3 3.1 ± 1.21 0.096 0.024 0.026 0.026 0.026 0.026 0.026 0.026 0.026 0.026 0.026 0.026 0.026 0.026 0.026 0.026 0.0		Yes	43	2.05 ± 1.13			0.31 ± 0.13			3.31 ± 1.16			0.56 ± 0.06		
	Hyperlipidemia	No	25	2.28 ± 1.34	0.225		0.36 ± 0.13	0.065		3.44 ± 1.16	0.275		0.55 ± 0.06	0.113	
Amputation No 53 188±1.25 0.138 0.32±0.14 0.154 3.29±1.21 0.265±0.06 0.200 0.010 Yes 5 2.49±1.47 0.43 0.34±0.12 0.44±0.12 0.456 0.25±0.06 0.65±0.06 0.655±0.06 0.655±0.06 0.655±0.06 0.655±0.06 0.60 0.00 Myocardial infarction Yes 5 2.49±1.47 0.432 0.34±0.13 0.446 3.52±1.15 0.066 0.55±0.06 0.20 0.01 Dabetes history 1 9 1.4±1.21 0.43 0.33±0.13 0.446 2.92±1.15 0.096 0.55±0.06 0.328 0.328 0.33±0.14 0.28 0.55±0.06 0.328 0.328 0.325±0.15 0.325±0.16 0.328 0.328 0.325±0.16 0.328 0.328 0.328±0.15 0.328±0.15 0.328±0.16 0.328±0.16 0.328±0.16 0.328±0.16 0.328±0.16 0.328±0.16 0.328±0.16 0.328±0.16 0.328±0.16 0.328±0.16 0.328±0.16 0.328±0.16 0.328±0.16 0.328±0.16<		Yes	33	1.88 ± 1.14			0.30 ± 0.13			3.24 ± 1.25			0.57 ± 0.06		
Ves 5 2.80 ± 0.84 0.40 ± 0.12 0.40 ± 0.12 0.37 ± 1.24 0.82 ± 0.05 0.65 ± 0.06 0.014 0.25 ± 0.06 0.014 0.22 ± 0.16 0.014 0.22 ± 0.16 0.014 0.026 ± 0.06 0.014 0.026 ± 0.06 0.014 0.021 0.014 0.021 0.014 0.021 0.014 0.021 0.014 0.021 0.014 0.021 0.014 0.021 0.014 0.021 0.014 0.021 0.014 0.021 0.014 0.021 0.014 0.021 <	Amputation	No	53	1.98 ± 1.25	0.138		0.32 ± 0.14	0.154		3.29 ± 1.21	0.262		0.55 ± 0.06	0.020	0.011
		Yes	ß	2.80 ± 0.84			0.40 ± 0.12			3.72 ± 1.24			0.62 ± 0.05		
No 14 1.79±142 0.36±0.18 3.53±1.55 0.55±0.05 Diabetes history 1 9 1.56±1.33 0.181 0.35±0.15 0.35±0.05 Type of diabetes 1 9 1.56±1.33 0.181 0.32±0.13 0.446 2.92±1.15 0.006 0.55±0.07 0.328 Diabetes history 58 +0.026 0.846 -0.141 0.289 0.161 0.451 0.326 0.07 0.328 Diabetes duration 58 +0.026 0.846 -0.141 0.289 0.014 0.451 0.326 0.07 0.328 Diabetes duration 58 +0.026 0.846 -0.141 0.289 0.014 0.021 0.026 0.03 0.142 0.334±1.05 0.031 0.027 0.328 0.142 0.328±0.17 0.338±1.29 0.344 0.026 0.036 0.014 0.021 0.026 0.036 0.014 0.021 0.026 0.036 0.014 0.021 0.027 0.348 0.026 0	Myocardial infarction	Yes	44	2.14 ± 1.17	0.432		0.31 ± 0.12	0.456		3.27 ± 1.08	0.964		0.56 ± 0.06	0.663	
Diabetes history Diabetes history 0.006 0.006 0.006 0.006 0.006 0.006 0.006 0.006 0.004 0.055±0.07 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.328 0.014 0.321 0.014 0.328 0.014 0.328 0.014 0.321 0.014 0.328 0.014 0.328 0.014 0.328 <th0.028< th=""> 0.014 <th0.021< th=""> <</th0.021<></th0.028<>		No	14	1.79 ± 1.42			0.36 ± 0.18			3.53 ± 1.55			0.55 ± 0.05		
Type of diabetes19 1.56 ± 1.33 0.181 0.29 ± 0.13 0.446 2.92 ± 1.15 0.096 0.55 ± 0.07 0.328 Type of diabetes249 2.14 ± 1.21 0.33 ± 0.14 0.33 ± 0.14 0.33 ± 0.14 0.33 ± 0.14 0.326 ± 0.06 0.014 0.55 ± 0.06 0.014 Diabetes duration58 $+0.554$ <0.0001 <0.0006 0.004 $+0.322$ 0.014 0.1272 0.039 Diabetes duration58 $+0.554$ <0.0001 <0.0001 <0.006 0.004 $+0.322$ 0.014 0.1272 0.039 Diabetes duration7836 $1.9411.40$ 0.32 ± 0.17 0.294 3.32 ± 1.45 0.014 0.272 0.014 Diabetes duration7836 2.14 ± 1.10 0.32 ± 0.17 0.294 3.32 ± 1.45 0.014 0.1272 0.039 Dial therapyNo10 2.30 ± 1.49 0.553 0.33 ± 0.17 0.294 3.34 ± 1.05 0.57 ± 0.04 0.26 ± 0.06 No10 2.30 ± 1.49 0.553 0.32 ± 0.15 0.33 ± 0.15 0.837 3.36 ± 1.29 0.237 0.55 ± 0.06 Ves8 -0.083 0.537 0.322 ± 0.13 0.33 ± 0.16 0.322 ± 1.19 0.25 ± 0.06 0.55 ± 0.06 No10 2.30 ± 1.49 0.557 0.232 ± 0.13 0.326 ± 1.19 0.232 ± 0.16 0.55 ± 0.07 0.55 ± 0.06 Ves50netical equivalent58 -0.083 0.774 -0.064 0.065 0.064 -0.056 0.074 <td>Diabetes history</td> <td></td>	Diabetes history														
2 49 2.14±1.21 0.33±0.14 0.33±0.14 0.33±0.14 0.35±0.06 0.0014 4.121 0.56±0.06 0.014 4.0.220 0.021 0.142 0.021 0.142 0.021 0.142 0.021 0.014 4.0.22 0.014 4.0.22 0.021 0.021 0.021 0.026	Type of diabetes		6	1.56 ± 1.33	0.181		0.29 ± 0.13	0.446		2.92 ± 1.15	0.096		0.55 ± 0.07	0.328	
Diabetes duration 58 +0.026 0.846 -0.141 0.289 -0.101 0.451 +0.320 0.014 HbA1C 58 +0.554 <0.0001		2	49	2.14 ± 1.21			0.33 ± 0.14			3.41 ± 1.21			0.56 ± 0.06		
HbA1C 58 +0.554 <0.0001 +0.437 0.006 0.004 +0.322 0.014 +0.272 0.039 Oral therapy No 22 1.91±1.44 0.424 0.32±0.17 0.294 3.32±1.45 0.344 0.021 +0.272 0.039 Oral therapy No 10 2.30±1.49 0.32±0.17 0.294 3.32±1.45 0.344 0.655±0.07 0.142 Nulin therapy No 10 2.30±1.49 0.553 0.33±0.15 0.837 3.36±1.29 0.237 0.56±0.05 0.142 Ves 36 2.14±1.10 0.32±0.15 0.837 3.36±1.19 0.237 0.206 Ves 2.00±1.19 0.533 0.32±0.13 0.32±0.13 3.36±1.19 0.237 0.206 Ves 2.00±1.19 0.533 0.33±0.13 3.26±1.19 0.237 0.206 0.56±0.06 0.065 Ves 2.00±1.19 0.134 0.36±1.19 0.234 0.55±0.06 0.206 0.56±0.06 0.068	Diabetes duration		58	+0.026	0.846		-0.141	0.289		-0.101	0.451		+0.320	0.014	
Oral therapy No 22 1.91 ± 1.44 0.424 0.32 ± 0.17 0.244 0.35 ± 0.07 0.142 Yes 36 2.14 \pm 1.10 0.33 ± 0.11 3.34 \pm 1.05 0.34 ± 0.05 0.55 ± 0.07 0.142 Insulin therapy Yes 36 2.14 \pm 1.10 0.33 ± 0.13 3.34 \pm 1.05 0.56 \pm 0.05 0.56 \pm 0.05 0.142 Insulin therapy No 10 2.30 \pm 1.49 0.553 0.33 \pm 0.13 3.34 \pm 1.05 0.57 \pm 0.04 0.206 Ves 48 2.00 \pm 1.19 0.32 \pm 0.13 3.26 \pm 1.19 0.237 0.57 \pm 0.06 0.56 \pm 0.05 0.142 Ves 2.00 \pm 1.19 0.32 \pm 0.13 3.26 \pm 1.19 0.237 0.56 \pm 0.06 0.065 0.074 0.074 0.065 0.019 0.07 0.019 0.07 0.014 0.05 0.016 0.05 0.05 0.07 0.01 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	HbA1C		58	+0.554	< 0.0001	<0.0001	+0.437	0.0006	0.004	+0.322	0.014	0.021	+0.272	0.039	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Oral therapy	No	22	1.91 ± 1.44	0.424		0.32 ± 0.17	0.294		3.32±1.45	0.344		0.55 ± 0.07	0.142	
Insulin therapy No 10 2.30±1.49 0.553 0.33±0.15 0.837 3.68±1.29 0.237 0.57±0.04 0.206 Ves 48 2.00±1.19 0.52±0.13 3.26±1.19 0.55±0.06 0.54±0.06 0.		Yes	36	2.14 ± 1.10			0.33 ± 0.11			3.34 ± 1.05			0.56 ± 0.05		
Ves 48 2.00±1.19 0.32±0.13 3.26±1.19 0.55±0.06 Oular characteristics 58 -0.083 0.537 -0.199 0.134 -0.038 0.774 -0.054 0.685 Spherical equivalent 58 -0.192 0.148 -0.124 0.354 -0.236 0.074 -0.307 0.019 0.07 BCVA 58 -0.192 0.148 -0.124 0.364 -0.236 0.074 -0.307 0.019 0.07 Lens status 41 1.85±1.20 0.065 0.30±0.12 0.033 0.012 3.12±0.98 0.074 0.056±0.06 0.339 Phakic 17 2.53±1.23 0.065 0.38±0.16 3.84±1.54 0.54±0.06 0.339	Insulin therapy	No	10	2.30 ± 1.49	0.553		0.33 ± 0.15	0.837		3.68 ± 1.29	0.237		0.57 ± 0.04	0.206	
Ocular characteristics Ocular characteristics Ocular characteristics 0.774 -0.054 0.685 0.685 0.068 0.019 0.019 0.013 0.774 -0.054 0.685 0.074 -0.054 0.685 0.019 0.001 0.016 0.019 0.001 0.019 0.001 0.019 0.001 0.019 0.001 0.019 0.001 0.019 0.001 0.019 0.001	Yes		48	2.00 ± 1.19			0.32 ± 0.13			3.26 ± 1.19			0.55 ± 0.06		
Spherical equivalent 58 -0.083 0.537 -0.199 0.134 -0.038 0.774 -0.054 0.685 BCVA 58 -0.192 0.148 -0.124 0.354 -0.236 0.074 -0.037 0.019 0.00 BCVA 58 -0.192 0.148 -0.124 0.354 -0.236 0.074 -0.307 0.019 0.00 Lens status 41 1.85±1.20 0.065 0.30±0.12 0.012 3.12±0.98 0.074 0.056±0.06 0.339 Phakic 17 2.53±1.23 0.065 0.38±0.16 3.84±1.54 0.54±0.06 0.339	Ocular characteristics														
BCVA 58 -0.192 0.148 -0.124 0.354 -0.236 0.074 -0.307 0.019 0.005 Lens status 41 1.85±1.20 0.065 0.30±0.12 0.012 3.12±0.98 0.074 0.056±0.06 0.339 Phakic 17 2.53±1.23 0.38±0.16 3.84±1.54 0.54±0.06 0.339	Spherical equivalent		58	-0.083	0.537		-0.199	0.134		-0.038	0.774		-0.054	0.685	
Lens status Phakic 41 1.85±1.20 0.065 0.30±0.12 0.033 0.012 3.12±0.98 0.074 0.026 0.56±0.06 0.339 Pseudophakic 17 2.53±1.23 0.38±0.16 0.38±0.16 3.384±1.54 0.56±0.06	BCVA		58	-0.192	0.148		-0.124	0.354		-0.236	0.074		-0.307	0.019	0.007
Phakic 41 1.85±1.20 0.065 0.30±0.12 0.012 3.12±0.98 0.074 0.026 0.55±0.06 0.339 Pseudophakic 17 2.53±1.23 0.38±0.16 0.38±0.16 0.38±0.16 0.38±0.16 0.339	Lens status														
Pseudophakic 17 2.53±1.23 0.38±0.16 3.84±1.54 0.54±0.06	Phakic		41	1.85 ± 1.20	0.065		0.30 ± 0.12	0.033	0.012	3.12 ± 0.98	0.074	0.026	0.56 ± 0.06	0.339	
	Pseudophakic		17	2.53 ± 1.23			0.38 ± 0.16			3.84 ± 1.54			0.54 ± 0.06		

Medicine

In this study, HbA1C was positively correlated with FAZ surface, FAZ perimeter, FAZ grade, and NPI. In previous studies, however, associations between HbA1C and macular microcirculation parameters have been inconsistently described. In patients either without or with background retinopathy, Sander et al^[31] found a significant correlation between HbA1C and perifoveal intercapillary area, but not with FAZ surface. Conrath et al^[14] likewise failed to find evidence of a correlation between FAZ indexes (surface, grade) and HbA1C.

Another positive correlation was observed between smoking status and FAZ grade and NPI, which is to our knowledge the first report of this association. In the context of diabetes, HbA1C and smoking correlated to the progression of FAZ and NPI indexes in NPDR patients could represent a mean to sensibilize this population.

We acknowledge some limitations to this study. Indeed, OCTA was not compared to FA, the gold standard for FAZ evaluation. However, in NPDR assessment this comparison could be considered as questionable on account of ethical considerations. The sample size of this study was relatively small, but it was an exploratory analysis and sample size was determined by the statistician (PI).

In conclusion, this study shows that OCTA is able to explore both superficial and deep macular capillary plexus in NPDR. With this noninvasive approach, progressive FAZ grade worsening and FAZ surface enlargement were observed during progression of NPDR. In addition, NPI, a newly described index, allows DMI assessment in a single automated and protocolized measurement taking into account both foveal and perifoveal microvascularization. Finally, even at early stages of diabetic retinopathy, HbA1C and smocking status seem to be associated with FAZ surface enlargement and NPI progression. If confirmed, these results could have therapeutic implications.

Acknowledgments

The authors thank Jeffrey ARSHAM, an American medical translator, for rereading and reviewing our original Englishlanguage text. We are indebt to Optovue RTVue XR Avanti for providing us a device during the study.

References

- [1] Whiting DR, Guariguata L, Weil C, et al. IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311–21.
- [2] Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA 2003;290:2057–60.
- [3] Liew G, Sim DA, Keane PA, et al. Diabetic macular ischaemia is associated with narrower retinal arterioles in patients with type 2 diabetes. Acta Ophthalmol 2015;93:e45–51.
- [4] Bresnick GH, Condit R, Syrjala S, et al. Abnormalities of the foveal avascular zone in diabetic retinopathy. Arch Ophthalmol 1984;102: 1286–93.
- [5] Bradley A, Applegate RA, Zeffren BS, et al. Psychophysical measurement of the size and shape of the human foveal avascular zone. Ophthalmic Physiol Opt 1992;12:18–23.
- [6] Ahmad Fadzil MH, Izhar LI, Nugroho HA. Determination of foveal avascular zone in diabetic retinopathy digital fundus images. Comput Biol Med 2010;40:657–64.
- [7] Ahmad Fadzil M, Ngah NF, George TM, et al. Analysis of foveal avascular zone in colour fundus images for grading of diabetic retinopathy severity. Conf Proc IEEE Eng Med Biol Soc 2010;5632–5.

- [8] Cennamo G, Vecchio EC, Finelli M, et al. Evaluation of ischemic diabetic maculopathy with Fourier-domain optical coherence tomography and microperimetry. Can J Ophthalmol J Can Ophtalmol 2015;50:44–8.
- [9] Alipour SHM, Rabbani H, Akhlaghi M, et al. Analysis of foveal avascular zone for grading of diabetic retinopathy severity based on curvelet transform. Graefes Arch Clin Exp Ophthalmol 2012;250: 1607–14.
- [10] Byeon SH, Chu YK, Lee H, et al. Foveal ganglion cell layer damage in ischemic diabetic maculopathy: correlation of optical coherence tomographic and anatomic changes. Ophthalmology 2009;116:1949–59.
- [11] Spaide RF, Klancnik JM, Cooney MJ. Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography. JAMA Ophthalmol 2015;133:45–50.
- [12] Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 2015;122:2044–52.
- [13] Ishibazawa A, Nagaoka T, Takahashi A, et al. Optical coherence tomography angiography in diabetic retinopathy: a prospective pilot study. Am J Ophthalmol 2015;160:35–44.
- [14] Conrath J, Giorgi R, Ridings B, et al. Metabolic factors and the foveal avascular zone of the retina in diabetes mellitus. Diabetes Metab 2005;31:465–70.
- [15] Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1995; 113:1144–55.
- [16] Garcia CR, Rivero ME, Bartsch D-U, et al. Oral fluorescein angiography with the confocal scanning laser ophthalmoscope. Ophthalmology 1999;106:1114–8.
- [17] Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:807–22.
- [18] Savastano MC, Lumbroso B, Rispoli M. In vivo characterization of retinal vascularization morphology using optical coherence tomography angiography. Retina 2015;35:2196–203.
- [19] Jia Y, Wei E, Wang X, et al. Optical coherence tomography angiography of optic disc perfusion in glaucoma. Ophthalmology 2014;121:1322–32.
- [20] Spaide RF, Klancnik JM, Cooney MJ. Retinal vascular layers in macular telangiectasia type 2 imaged by optical coherence tomographic angiography. JAMA Ophthalmol 2015;133:66–73.
- [21] Arend O, Remky A, Evans D, et al. Contrast sensitivity loss is coupled with capillary dropout in patients with diabetes. Invest Ophthalmol Vis Sci 1997;38:1819–24.
- [22] Unoki N, Nishijima K, Sakamoto A, et al. Retinal sensitivity loss and structural disturbance in areas of capillary nonperfusion of eyes with diabetic retinopathy. Am J Ophthalmol 2007;144:755–60.
- [23] Sakata K, Funatsu H, Harino S, et al. Relationship of macular microcirculation and retinal thickness with visual acuity in diabetic macular edema. Ophthalmology 2007;114:2061–9.
- [24] Bek T. Transretinal histopathological changes in capillary-free areas of diabetic retinopathy. Acta Ophthalmol 1994;72:409–15.
- [25] Arend O, Wolf S, Jung F, et al. Retinal microcirculation in patients with diabetes mellitus: dynamic and morphological analysis of perifoveal capillary network. Br J Ophthalmol 1991;75:514–8.
- [26] Arend O, Wolf S, Remky A, et al. Perifoveal microcirculation with noninsulin-dependent diabetes mellitus. Graefes Arch Clin Exp Ophthalmol 1994;232:225–31.
- [27] Mansour AM, Schachat A, Bodiford G, et al. Foveal avascular zone in diabetes mellitus. Retina 1993;13:125–8.
- [28] Bresnick GH, Condit R, Syrjala S, et al. Abnormalities of the foveal avascular zone in diabetic retinopathy. Arch Ophthalmol 1984;102: 1286–93.
- [29] Arend O, Wolf S, Harris A, et al. THe relationship of macular microcirculation to visual acuity in diabetic patients. Arch Ophthalmol 1995;113:610–4.
- [30] Sim DA, Keane PA, Zarranz-Ventura J, et al. The effects of macular ischemia on visual acuity in diabetic retinopathy. Investig Opthalmology Vis Sci 2013;54:2353.
- [31] Sander B, Larsen M, Engler C, et al. Early changes in diabetic retinopathy: capillary loss and blood-retina barrier permeability in relation to metabolic control. Acta Ophthalmol 1994;72:553–9.